181 related articles for article (PubMed ID: 30707464)
1. Non-secretory breast carcinomas lack NTRK rearrangements and TRK protein expression.
Remoué A; Conan-Charlet V; Bourhis A; Flahec GL; Lambros L; Marcorelles P; Uguen A
Pathol Int; 2019 Feb; 69(2):94-96. PubMed ID: 30707464
[TBL] [Abstract][Full Text] [Related]
2. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
[TBL] [Abstract][Full Text] [Related]
3. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
Hung YP; Jo VY; Hornick JL
Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
[TBL] [Abstract][Full Text] [Related]
5. Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.
Harrison BT; Fowler E; Krings G; Chen YY; Bean GR; Vincent-Salomon A; Fuhrmann L; Barnick SE; Chen B; Hosfield EM; Hornick JL; Schnitt SJ
Am J Surg Pathol; 2019 Dec; 43(12):1693-1700. PubMed ID: 31498178
[TBL] [Abstract][Full Text] [Related]
6. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
8. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
[TBL] [Abstract][Full Text] [Related]
9. Fluorescent In Situ Hybridization Must be Preferred to pan-TRK Immunohistochemistry to Diagnose NTRK3-rearranged Gastrointestinal Stromal Tumors (GIST).
Castillon M; Kammerer-Jacquet SF; Cariou M; Costa S; Conq G; Samaison L; Douet-Guilbert N; Marcorelles P; Doucet L; Uguen A
Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):626-634. PubMed ID: 33758144
[TBL] [Abstract][Full Text] [Related]
10. Screening for NTRK-rearranged Tumors Using Immunohistochemistry: Comparison of 2 Different pan-TRK Clones in Melanoma Samples.
Bourhis A; Redoulez G; Quintin-Roué I; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):194-196. PubMed ID: 30920961
[TBL] [Abstract][Full Text] [Related]
11. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
[TBL] [Abstract][Full Text] [Related]
12. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
[TBL] [Abstract][Full Text] [Related]
13. NTRK gene fusions are detected in both secretory and non-secretory breast cancers.
Maund SL; Sokol ES; Ang Houle A; Ross JS; Wilson TR
Pathol Int; 2022 Mar; 72(3):187-192. PubMed ID: 35102630
[TBL] [Abstract][Full Text] [Related]
14. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
[TBL] [Abstract][Full Text] [Related]
15. Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry.
Sholl LM; Zheng M; Nardi V; Hornick JL
Histopathology; 2021 Aug; 79(2):260-264. PubMed ID: 33682174
[TBL] [Abstract][Full Text] [Related]
16. Identifying patients with NTRK fusion cancer.
Solomon JP; Benayed R; Hechtman JF; Ladanyi M
Ann Oncol; 2019 Nov; 30(Suppl_8):viii16-viii22. PubMed ID: 31738428
[TBL] [Abstract][Full Text] [Related]
17. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
[TBL] [Abstract][Full Text] [Related]
18. Limited Accuracy of Pan-Trk Immunohistochemistry Screening for
Macerola E; Proietti A; Poma AM; Vignali P; Sparavelli R; Ginori A; Basolo A; Elisei R; Santini F; Basolo F
Int J Mol Sci; 2022 Jul; 23(13):. PubMed ID: 35806472
[TBL] [Abstract][Full Text] [Related]
19. The Genomic and Proteomic Profiles of NTRK Genes and Trk Receptors in Liver Hepatocellular Carcinoma.
Wang H; Qi L; Zhong C; Fang X; Yuan Y
Clin Med Insights Oncol; 2023; 17():11795549231180840. PubMed ID: 37456611
[TBL] [Abstract][Full Text] [Related]
20. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
Wagner F; Greim R; Krebs K; Luebben F; Dimmler A
Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]